Global Influenza Vaccine Market Expected to Grow with a CAGR of 5.9% by 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Influenza Vaccine Market by Vaccine Type, Type, Technology, Age Group, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

The global influenza vaccine market was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026.

Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal method to prevent influenza is through vaccination.

The key factors that drive the growth of the global influenza vaccine market include increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, upsurge in funding and investments by companies in R&D activities supplements the growth of this market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. Conversely, routine immunization programs in developed and developing countries are expected to provide lucrative opportunities for market expansion.

The global influenza vaccines market is segmented into vaccine type, type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. Depending on type, it is segregated into seasonal and pandemic. As per technology, it is classified into egg-based and cell-based. According to age group, it is divided into pediatric and adult. On the basis of route of administration, it is categorized into injection and nasal spray. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
  • An inodepth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate regionospecific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global influenza vaccine market is provided.
  • An extensive analysis of various regions provides insights that allows companies to strategically plan their business moves.

Key Findings of the Influenza Vaccine Market:

  • Based on technology, the egg-based segment was the major revenue contributor in 2018 and is anticipated to continue this trend during the forecast period.
  • Based on age group, its pediatric segment is expected to exhibit the highest CAGR with 6.1% during the forecast period.
  • Depending on route of administration, the injection segment was the largest revenue contributor in 2018 and is expected to continue this trend from 2019 to 2026.
  • U.S. generated the highest revenue in the global influenza vaccine market in 2018, accounting for more than two-fifth of the global market in 2018.
  • LAMEA is estimated to grow at the highest CAGR during the forecast period.

Key Topics Covered:

Chapter 1: Introduction

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

1.4. Research Methodology

Chapter 2: Executive Summary

2.1. Key Findings of The Study

2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter'S Five Force Analysis

3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. High Prevalence of Influenza

3.4.1.2. Increase In Government Focus On Immunization Programs

3.4.1.3. Emerging Vaccines

3.4.1.4. Technological Progress In Vaccine Administration

3.4.2. Restraints

3.4.2.1. Longer Timelines And Implementation of Stringent Regulations

3.4.2.2. High Costs Associated With The Development of Vaccines

3.4.3. Opportunity

3.4.3.1. High Growth Prospects In Emerging Markets

Chapter 4: Influenza Vaccine Market, By Vaccine Type

4.1. Overview

4.2. Quadrivalent

4.3. Trivalent

Chapter 5: Influenza Vaccine Market, By Type

5.1. Overview

5.2. Seasonal Influenza Vaccine

5.3. Pandemic Influenza Vaccine

Chapter 6: Influenza Vaccine Market, By Technology

6.1. Overview

6.2. Egg-Based

6.3. Cell Culture

Chapter 7: Influenza Vaccine Market, By Age Group

7.1. Overview

7.2. Pediatric

7.3. Adult

Chapter 8: Influenza Vaccine Market, By Route of Administration

8.1. Overview

8.2. Injection

8.3. Nasal Spray

Chapter 9: Global Influenza Vaccine Market, By Region

9.1. Overview

9.2. North America

9.3. Europe

9.4. Asia-Pacific

9.5. LAMEA

Chapter 10: Company Profiles

10.1. Astrazeneca Plc

10.2. Biodiem

10.3. Csl Limited

10.4. Emergent Biosolutions

10.5. F. Hoffmann-La Roche Ltd.

10.6. Gamma Vaccines Pty Ltd.

10.7. Glaxosmithkline Plc

10.8. Merck & Co., Inc.

10.9. Novartis Ag

10.10. Pfizer, Inc.

10.11. Sanofi

10.12. Sinovac Biotech Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/h0q1ef

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900